medi7352
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 17, 2015 (NCT02508155)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
- Beta-nerve growth factorINHIBITOR
NGF inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- medi7352
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04770428 | Phase 1 | Apr 20, 2021 | AstraZeneca |
| NCT04675034 | Phase 2 | Dec 2, 2020 | AstraZeneca |
| NCT03755934 | Phase 2 | Nov 19, 2018 | AstraZeneca |
| NCT02508155 | Phase 1 | Nov 17, 2015 | AstraZeneca, Bio-Kinetic Clinical Applications |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2015 |
| Bio-Kinetic Clinical Applications | For profit | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1